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Background & the purpose of the study: Prevalence of type 2 diabetes mellitus (T2DM) is increasing worldwide.
To reduce its risk and progression, preventive strategies are needed. Vitamin supplementation such as vitamin D is
one of the strategies. This study was designed to investigate the effect of injection of vitamin D on insulin
resistance and anthropometric parameters in T2DM.
Methods: This randomized double-blind clinical trial was conducted with 42 diabetic patients in two groups;
intervention group with single intramuscular injection of 300,000 International Unit (IU) of vitamin D3 and the
placebo group. After recording demographic and anthropometric factors (waist circumference, blood pressure and
body mass index), fasting blood samples was taken for measurement of blood glucose, 25-hydroxyvitamin D3 (25-
OHD3), insulin, glycosylated hemoglobin A1c (HbA1c) and estimation of Homeostasis Model Assessment Index
(HOMA) in two times; before study and after three months.
Results: Two groups had similar baseline characteristics (each group= 21 subjects). Three months after vitamin D
injection, HbA1c, anthropometric factors and HOMA index in intervention group stayed constant, however, serum
25- OHD3 was significantly increased (p = 0.007).
Conclusion: The present data is not convincing and further studies with large sample sizes are needed to show
the definite effect of injection of vitamin D on control of diabetes and its risk.
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Prevalence of type 2 diabetes mellitus (T2DM) is in-
creasing worldwide. Nowadays over 360 million people
are suffering from diabetes and it is expected that its
prevalence reach a staggering 552 million by 2030 [1].
T2DM is defined by impaired glucose tolerance, chronic
hyperglycemia, altered insulin secretion, and complica-
tions that come from induction of oxidative stress [2].
One of novel strategy toward prevention and control of
T2DM is vitamin D supplementation. Besides the role
of vitamin D in calcium homeostasis and bone metabol-
ism, other effects also have been proposed for this* Correspondence: otabatabaeimla@yahoo.com
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distribution, and reproduction in any mediummineral. Vitamin D is essential for normal insulin secre-
tion in response to glucose and also for maintenance of
glucose tolerance [3-6]. In a study performed on 126
healthy adults with normal blood glucose, an associ-
ation between vitamin D deficiency with beta cell dys-
function and insulin resistance was observed [7]. Such
an association has also been established in type 1 dia-
betes mellitus (T1DM) [8-11]. Though little information
is available regarding the association between vitamin D
and T2DM [6]. Human and animal studies have shown
a negative correlation between serum levels of vitamin
D with serum glucose and insulin levels and a positive
correlation with insulin sensitivity [5,6]. Several pro-
cesses are responsible for effect of vitamin D on metab-
olism of glucose and insulin. Some animal studies have
suggested that vitamin D may directly stimulate thetral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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and also subjects with high blood sugar, consumption
of vitamin D supplement improved the insulin secretion
[7,12,13]. However, interventional studies have shown
conflicting results about the effect of vitamin D supple-
ment on T2DM [6,7,12,14-16]. These differences can be
related to difference in race, dosage of vitamin D ad-
ministration (oral or injection), or duration of usage. To
best of our knowledge, no study has assessed the effect
of injected mode of vitamin D supplement on diabetes
in Iranian population. In this study we evaluated the ef-
fect of injected vitamin D supplement on insulin resist-
ance and anthropometric parameters.
Materials and methods
Study population
This randomized double-blind clinical trial was per-
formed with 42 diabetic patients, chosen from diabetes
clinic of Dr. Shariati Hospital/Tehran. Diabetes was
diagnosed according to American Diabetes Association
criteria [17]. Inclusion criteria were T2DM subjects’
undertreatment diet and/or oral hypoglycemic agents’
treatment with glycosylated hemoglobin A1c≤ 7.5%.
(HbA1c). Exclusion criteria included: insulin therapy,
patient’s reluctance to continue cooperating in every
stage of the project, known clinical deficiency of vita-
min D, current consumption of vitamin D, multivitamin
or calcium, renal failure, nephrotic syndrome, liver fail-
ure, known cases of liver cirrhosis or liver dysfunction
associated with ascites, hypoalbuminemia, coagulation
disorders, and uncontrolled blood pressure. The patient
who received the vitamin D injection in the past six
months was also excluded from study. After obtaining
the written consent, a baseline fasting blood samples
was obtain from all the patients. The patients then in a
random double blind manner were divided into two
groups; intervention group who received a single intra-
muscular injection of 300000 International Unit (IU)
vitamin D3, and placebo group. Each group included 21
subjects and examined in two time points: baseline and
three months after vitamin D administration (mean of
92 days) for anthropometric characteristics (systolic and
diastolic blood pressure, body mass index (BMI), waist
circumference) and biochemical analysis including fast-
ing blood sugar (FBS), 25 - hydroxyvitamin D3 (25-
OHD3), insulin, and HbA1c levels. BMI was calculated
using following formula: weight (kg)/height2 (m). Waist
circumference was measured on broadest area between
the edge of lower ribs and the iliac crest. Systolic and
diastolic blood pressure was measured after 5–10 min
rest, on the right arm in sitting position. The study was
approved by ethical committee of EMRC and registered
in the Iranian Registry of clinical trials (IRCT) with
code number of IRCT1138901221414N12.Laboratory methods
FBS was measured using photometric assay performed
with an autoanalyser Hitachi 902, Pars- Azmon kit/Iran.
Insulin and 25-OHD3 levels were measured by ELISA
assay using kit Monobound Company (USA) and IDS
(USA) respectively. DS5 chromatography Drew Scientific
Limited Company (UK) was used for HbA1c measure-
ment. For estimation of insulin resistance the Homeosta-
sis Model Assessment Index (HOMA) based on the
following equation was used [18].
HOMA=Fasting plasma insulin (μIU/ml) * fasting
blood sugar (mg/dl)/405 The HOMA index value < 3
was considered as normal and ≥ 3 as insulin resistant
[19]. 25-OHD3 levels equal to: ≤ 21, 21–29, and ≥ 30 ng/
ml were defined as deficient, inadequate, and adequate
vitamin D [20,21], respectively. All of the laboratory tests
were done in one hormone laboratory.Statistical analysis
The normal distribution of data was evaluated by
Kolmogrov-Smirnov analytic test. Paired T-Test was ap-
plied for variables with normal distribution, and Wil-
coxon and Mann–Whitney nonparametric tests for
others. All the statistical analysis was performed with
SPSS software version 15. P ≤ 0.05 was considered as sta-
tistically significant.Results
Majority of the participants (64%) were composed of
female subjects. The age range of patients was 37–
79 years with a mean of 56 years and diabetes dur-
ation of 5 ± 7 years (mean ± SD). All the patients were
under oral hypoglycemic agents (OHA) treatment ex-
cept in two patients (4.8%) who were on diet therapy
for controlling their blood sugar. The OHA treatment
of participants was as follow: 16 subjects (38.1%) on
combination therapy with metformin and glibencla-
mide, 9 subjects (21.4%) on glibenclamide, 7 subjects
(16.7%) on combination of metformin, glibenclamide,
and acarbose, 6 subjects (14.3%) on metformin, and 2
patients (4.8%) on combination of metformin and acar-
bose. No significantly difference between two groups
was present in regards to their anti-diabetic treatment
regimen (p = 0.541).
Baseline characteristics of intervention and placebo
groups are described in Table 1.
All variables had normal distribution except 25-OHD3
and insulin. Two groups showed no significant differences
in anthropometric or clinical characteristics. Table 2
shows the mean differences in both anthropometric and
clinical parameters, three months after vitamin D injec-
tion between interventional and placebo groups.
Table 1 Baseline anthropometric and biochemical characteristics of patients in both intervention and placebo groups
Variable Intervention group (n= 21) Placebo group (n= 21) P value
Age (yr) 56.2 ± 9.3 56.2 ± 11 0.988
Male/Female (%(n)) 7 (16.7)/14 (33.3) 8 (19)/13 (31) 1.000
Duration of diabetes (yr) 6.7 ± 4.1 7.9 ± 6.1 0.455
SBP (mmHg) 120.9 ± 9.9 116.6 ± 31.5 0.566
DBP (mmHg) 79.7 ± 10 83.9 ± 18.4 0.331
WC (cm) 92.2 ± 6.7 91.3 ± 8.7 0.945
BMI (kg/m2) 27.7 ± 3.4 28.5 ± 3.9 0.484
FBS (mg/dl) 133.5 ± 23.7 138.9 ± 31.3 0.526
HbA1c (%) 6.5 ± 0.9 6.7 ± 0.9 0.598
Insulin (μIU/ml)* 9.2 ± 4.9 10.4 ± 4.7 0.354
HOMA* 3.1 ± 2.3 3.4 ± 1.5 0.145
25-OHD3 (ng/ml) * 46.9 ± 34.7 35.3 ± 36.1 0.212
Legend: SBP: Systolic Blood Pressure, DBP: Diastolic Blood Pressure, WC: Waist Circumference, BMI: Body mass Index, FBS: Fasting Blood Sugar, HbA1c: Glycated
Hemoglobin A1c, HOMA: Homeostasis Model Assessment Index, 25-OHD3: 25-Hydroxy vitamin D3.
The results are described as mean ± Standard Deviation (SD).
* The Wilcoxon and Mann–Whitney nonparametric test was used. Paired T-Test was used for other variables.
P≤ 0.05 was considered as statistically significant.
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In our study the effect of a single intramuscular injection
of 300,000 IU vitamin D (cholecalciferol) in a short
period (92 days) in the diabetic patients was evaluated.
We found a significant increase in serum 25-OHD3
levels in interventional group without any significant
change in level of HbA1c, anthropometric factors, and
HOMA index. On the other word, administration of
vitamin D in diabetic subjects produced negative effects
on control of glycemic status and insulin resistance.
Detecting an increase in serum levels of 25-OHD3 in
diabetic subjects following vitamin D injection is in
agreement to result of Rahimi et al. [22]. They found a
single administration of 600,000 IU cholecalciferol inTable 2 Comparison anthropometric and biochemical
characteristics before and three months after study
according to mean differences
Variable Intervention group Placebo group P value
SBP (mmHg) 1.1 ± 0.2 1.1 ± 0.4 0.763
DBP (mmHg) 0.9 ± 0.2 1 ± 0.2 0.394
WC (cm) 0.3 ± 3.3 0.9 ± 3.8 0.617
BMI (kg/m2) 0.08 ± 0.5 −0.3 ± 0.9 0.160
FBS (mg/dl) 16.2 ± 29.2 −9.7 ± 30 0.007**
HbA1c (%) −0.01 ± 0.9 −0.2 ± 0.9 0.495
Insulin (μIU/ml)* −0.2 ± 3.6 −2.4 ± 4.2 0.052**
HOMA* 0.2 ± 1.4 −0.9 ± 1.6 0.017**
25-OHD3 (ng/ml) * 22.4 ± 39.9 0.5 ± 17.4 0.009**
Legend: SBP: Systolic Blood Pressure, DBP: Diastolic Blood Pressure, WC: Waist
Circumference, BMI: Body mass Index, FBS: Fasting Blood Sugar, HbA1c:
Glycated Hemoglobin A1c, HOMA: Homeostasis Model Assessment Index,
25-OHD3: 25-Hydroxy vitamin D3.
The results are described as mean ± Standard Deviation (SD).
* Wilcoxon and Mann–Whitney analytic test was used.
** P≤ 0.05 was considered statistically significant.obese women could significantly increase (p <0.001) the
serum 25-OHD3 concentration two weeks after injec-
tion. It has been previously reported that a single admin-
istration of 100,000 IU of vitamin D is a safe, effective
and simple way to increase the serum levels of calcidiol.
To ensure the continuity of vitamin D level above the
baseline, the injection intervals of not more than two
months has been recommended [23]. In our study, the
median level of serum 25-OHD3 after 92 days was above
the baseline, equal 78 ng/ml.
Series of studies have shown that a positive correlation
between low levels of serum 25-OHD3 and impaired in-
sulin sensitivity [24-26], T2DM, hypertension, hyperlip-
idemia and obesity is exist [7]. An inverse relationship
has been reported between serum 25-OHD3 levels and
HbA1c, particularly in obese patients [27]. In a cohort
study with 17 years follow up, a significant inverse rela-
tion between serum levels of serum 25-OHD3 and inci-
dence of T2DM was observed [28]. Indeed a protective
role for high levels of plasma vitamin D against T2DM
progression has been reported [29]. However, in inter-
ventional studies, there are some conflicting results
regarding the effect of vitamin D in prevention of
T2DM.
Some studies performed that in population with con-
comitant vitamin D deficiency and impaired glucose tol-
erance or T2DM, vitamin D supplement was able to
correct the insulin secretion and glucose tolerance
[12,30], as well as HbA1c [31]. In contrast, some studies
failed to show an improvement in levels of blood sugar,
glucose tolerance or insulin sensitivity following vitamin
D supplement in both diabetic and non-diabetic subjects
[4,32-35]. These controversy, or at least part of it, might
be due to ethnicity difference in study’s population [6].
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Survey (NHANES III) showed an inverse relation be-
tween vitamin D status and diabetes in non-Hispanic
whites and Mexican Americans, but not in non-Hispanic
blacks [36]. Other reasons for discrepancy seen in differ-
ent studies might be related to duration of study, sample
size, and lack of prospective studies or clinical trials spe-
cifically aimed to evaluate the effect of vitamin D defi-
ciency on the incidence of T2DM [37]. Dosage or
formulation of intake vitamin D may also be considered.
Conflicting results on metabolism of glucose and insulin
[4,12-14,30,33,34,38-42] has been observed by adminis-
tration of different forms of vitamin D such as cholecal-
ciferol, orgocalciferol, and active form of this vitamin.
In our study the baseline level of HOMA index in
two groups were similar. Interestingly, no remarkable
changes in HOMA index following vitamin D injection
in intervention group was found, while in placebo
group a significant decrease at the end of study was
noticed (mean difference =−0.09). In contrast to our
result, in a study performed with 33 non-diabetics
vitamin D deficient patients, two oral doses of
100,000 IU cholecalciferol corrected the vitamin D de-
ficiency after two weeks without affecting on the glu-
cose or insulin levels [43]. In the other study with 32
diabetic patients under metformin and bedtime insulin
treatment, consumption of 40,000 IU weekly cholecal-
ciferol for 6 months had no effect on fasting blood
sugar, insulin, c-peptide and HbA1c compared with
placebo group [44]. One assumption could be that
since insulin secretion is a calcium dependent process,
it can indirectly be influenced by effect of vitamin D
on calcium absorption. Although a single injection of
vitamin D caused significant changes in serum levels
of vitamin D, the insulin resistant status has become
worsen [44]. On the other word, for improvement of
insulin resistant we need to consume a combination of
calcium and vitamin D. Meta-analysis of observational
and interventional studies have shown that insufficient
supplement of vitamin D and calcium has a negative
effect on blood glucose while combination therapy was
more useful on obtaining optimal glucose metabolism
[37]. The observed changes in blood sugar and insulin
level between our two groups three months after
intervention might be related to difference in their
nutritional status. We cannot exactly address this as-
sumption because of unfilled Food Frequency Ques-
tionnaire (FFQ) for patients in this study and also
because of unawareness of amount of calcium intake
in diet of our subjects. It seems that the effect of vita-
min D on glucose intolerance is more prominent in
vitamin D deficient patients [45]. Due to our small
sample size in each group, it is impossible to classify
our patients according to their vitamin D status.Similar to our study, one study evaluated three diabetic
vitamin D deficient patients after receiving a single intra-
muscular injection of 300,000 IU orgocalciferol. In this
study, three months after injection, undesirable effects
on blood sugar and insulin resistance was observed [15].
Obesity is determined as one of the proven risk factors
for T2DM. There are several reports that shown an in-
verse relationship between vitamin D levels and obesity,
even in different definition of obesity according to
weight, BMI and waist circumference [46-50]. This cor-
relation has been seen in both sexes who were not sever
obese [51] and is not depend on dose of vitamin D sup-
plements provided for the patients [52]. However in our
study such an association between vitamin D levels and
BMI or WC was not found. In New Zealand study [36]
also such a correlation was not observed.
One study assessed the results of 14 interventional
studies about the effect of vitamin D administration
on glucose metabolism and insulin resistance in non-
diabetic and diabetic patients [43]. They concluded
that the most of these studies could not clearly deter-
mine an effective change in blood sugar concentrations
following administration of vitamin D. Additionally, by
these studies, it is difficult to clear that whether vitamin
D or calcium therapy are effective in prevention of dia-
betes or their effects are presented just in subjects who
are at risked to diabetes development. In a systematic
review [37] summarizing clinical trials focusing on effect
of vitamin D and or calcium in prevention of metabolic
syndrome and T2DM, the authors concluded that by
these small clinical studies or using post hoc analysis it
is difficult to describe whether vitamin D or calcium is
effective in prevention of T2DM or its effect is more
visible just in people at risk of T2DM. On the other
word epidemiologic studies suggested the relationship
between low level of vitamin D and impaired glucose
tolerance, but intervention studies showed the conflict-
ing results [53].
Most diabetic subjects also suffer from hypertension
[54]. Cross-sectional studies have shown an inverse rela-
tion between serum levels of vitamin D (even at normal
levels) with blood pressure in people with high or nor-
mal blood pressure [55,56]. In a large cohort study [57]
the relative risk of progression of hypertension in low
levels of 25-OHD3 during 4–8 years follow up, was 6.1
in men and 2.7 in women compared with individuals
with normal levels of vitamin D. In an interventional
study [58] was found the combined consumption of vita-
min D and calcium in elderly women with low levels of
25-OHD3, could produce significant reduction in sys-
tolic blood pressure (mean 5 mmHg) and in heart rate
comparison calcium supplement alone. In our study, ad-
ministration of vitamin D had no significant effect on
systolic or diastolic blood pressure.
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of our patients were diabetic and none of them were
undertreatment with insulin. Moreover, the duration of
follow up and method of our study was different from
previous studies. One assumption for not seeing the ef-
fect of vitamin D in our study would be that three
months is not enough to see the effects of vitamin D
therapy on metabolism of glucose and insulin, though
the positive expected effects from vitamin D to increase
serum 25-OHD3 levels is produced. It should be noted
that affecting the serum levels of vitamin D by supple-
ment consumption can be achieved in times shorter
than even a day after single intravenous administration
of 1, 25-dihydroxy D [39]. One of limitation in our study
was our small sample size. Additionally, our patients
were evaluated regardless of their baseline levels of
25-OHD3, calcium and phosphor or unfilled FFQ. La-
boratory assays used to determine the circulating level
of vitamin D was our another limitation. There are dif-
ferent assays to measure 25-OHD3 levels (59). Immuno-
assay and Competitive Protein Binding assay are suitable
methods; however, LC-MS method that is capable of
simultaneously measuring 25-OHD2 and 25-OHD3 con-
centration is more convenient [58]. Future studies to
evaluate effects of concomitant consumption of vitamin
D and calcium, effect of vitamin D in patients with vita-
min D insufficiency, along with attention to larger sam-
ple sizes is suggested.Conclusion
Based on previous results; by this study we cannot be
sure the effect of single injection of vitamin D on dia-
betes control and improvement of insulin resistance.
Taken our data together available information warrants
exploring the possibility that vitamin D in combination
with calcium supplementation can be more efficient in
reducing T2DM risk than intake of vitamin D alone.
Moreover further studies are needed to show the definite
effect of injection of vitamin D on control of diabetes
and its risk.
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